Incyclix Bio
Durham, United States (US) · Health and Medical
We built this page from public sources.
Do you work at Incyclix Bio?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Incyclix Bio is a Health and Medical company based in Durham, United States (US), founded in 2020, with 2-10 employees. Incyclix Bio's profile is verified on Enterprise League.
Overview
Incyclix Bio is a Durham, North Carolina-based biotechnology company pioneering precision oncology treatments.
We are dedicated to regaining cell cycle control in patients with advanced cancers by developing potent and selective cyclin-dependent kinase 2 (CDK2) inhibitors. Our scientific leadership focuses on understanding and targeting the aberrant proliferation driving various tumor types, including ovarian, breast, and lung cancers.
Founded by experts with a proven track record in CDK inhibitor discovery and development, Incyclix Bio leverages decades of combined experience to bring innovative therapies to patients in need. We are committed to advancing novel CDK inhibitors to address unmet medical needs and improve patient outcomes.
Incyclix Bio’s team has a history of successful drug development, originating from the foundation of G1 Therapeutics, where they pioneered the myelopreservation concept and successfully advanced trilaciclib to clinical trials.
We are dedicated to regaining cell cycle control in patients with advanced cancers by developing potent and selective cyclin-dependent kinase 2 (CDK2) inhibitors. Our scientific leadership focuses on understanding and targeting the aberrant proliferation driving various tumor types, including ovarian, breast, and lung cancers.
Founded by experts with a proven track record in CDK inhibitor discovery and development, Incyclix Bio leverages decades of combined experience to bring innovative therapies to patients in need. We are committed to advancing novel CDK inhibitors to address unmet medical needs and improve patient outcomes.
Incyclix Bio’s team has a history of successful drug development, originating from the foundation of G1 Therapeutics, where they pioneered the myelopreservation concept and successfully advanced trilaciclib to clinical trials.
Contact Details
+1919-328-0003
info@incyclixbio.com
Durham, United States (US), 600 Park Office Dr
Founded
2020
Company Type
Private Limited Company
Employees
2-10
Categories
Companies teams usually look at after Incyclix Bio
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.